AI MARKET SCANNING

Sagimet Biosciences Inc-A

📅 Next Catalyst: Nov 12, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Health Technology 🏭 Pharmaceuticals Major
AVG HISTORICAL GAP +1.46%
MAX GAP RECORD -6.24%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $SGMT
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 12, 2026 Earnings Release 2026-11-12 (BEFORE OPEN) 🔮 UPCOMING 🔒
Aug 12, 2026 Earnings Release 2026-08-12 (AFTER CLOSE)
+1.38%
May 12, 2026 Earnings Release 2026-05-12 (BEFORE OPEN)
-1.30%
Mar 11, 2026 Earnings Release 2026-03-11 (BEFORE OPEN)
+4.34%
Nov 13, 2025 Earnings Release 2025-11-13 (BEFORE OPEN)
-6.24%
Aug 13, 2025 Earnings Release 2025-08-13 (AFTER CLOSE)
-1.77%
May 07, 2025 Earnings Release 2025-05-07 (AFTER CLOSE)
+3.29%
Mar 12, 2025 Earnings Release 2025-03-12 (BEFORE OPEN)
+2.80%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.2%
Bullish Gaps (8)
Bearish Gaps (3)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $SGMT

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-08-12 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 119m +0.60%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗